Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

4 of 2 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01088789Phase 2Active Not Recruiting

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Role: collaborator

NCT01595321Phase 2Completed

Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas

Role: collaborator

NCT00389610Phase 2Completed

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer

Role: collaborator

NCT01431794Phase 1Terminated

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Role: collaborator

All 4 trials loaded